LJI Wealth Management LLC Has $5.51 Million Holdings in Eli Lilly and Company (NYSE:LLY)

LJI Wealth Management LLC boosted its position in Eli Lilly and Company (NYSE:LLY) by 1.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,131 shares of the company’s stock after buying an additional 127 shares during the period. Eli Lilly and Company makes up 1.1% of LJI Wealth Management LLC’s holdings, making the stock its 15th biggest holding. LJI Wealth Management LLC’s holdings in Eli Lilly and Company were worth $5,505,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the company. HTLF Bank boosted its holdings in shares of Eli Lilly and Company by 7.3% during the 4th quarter. HTLF Bank now owns 828 shares of the company’s stock worth $639,000 after buying an additional 56 shares in the last quarter. Tevis Investment Management lifted its position in shares of Eli Lilly and Company by 62.8% during the 4th quarter. Tevis Investment Management now owns 1,506 shares of the company’s stock valued at $1,163,000 after acquiring an additional 581 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA boosted its stake in Eli Lilly and Company by 37.0% during the fourth quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 9,855 shares of the company’s stock worth $7,965,000 after acquiring an additional 2,660 shares in the last quarter. Washburn Capital Management Inc. grew its holdings in Eli Lilly and Company by 3.0% in the fourth quarter. Washburn Capital Management Inc. now owns 2,680 shares of the company’s stock worth $2,069,000 after purchasing an additional 77 shares during the period. Finally, Compass Financial Services Inc bought a new stake in Eli Lilly and Company in the fourth quarter valued at $50,000. Institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on LLY shares. Wells Fargo & Company cut their price objective on shares of Eli Lilly and Company from $1,000.00 to $970.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 28th. Truist Financial increased their price target on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a report on Monday, February 3rd. Deutsche Bank Aktiengesellschaft lowered their target price on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating on the stock in a research report on Monday, November 4th. Sanford C. Bernstein initiated coverage on shares of Eli Lilly and Company in a research report on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 price target for the company. Finally, Redburn Atlantic upgraded shares of Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th. Four equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $997.50.

Eli Lilly and Company Stock Down 1.1 %

Shares of NYSE LLY opened at $868.57 on Tuesday. The stock has a market capitalization of $824.55 billion, a P/E ratio of 74.17, a PEG ratio of 1.87 and a beta of 0.42. Eli Lilly and Company has a one year low of $711.40 and a one year high of $972.53. The firm’s 50 day simple moving average is $789.87 and its two-hundred day simple moving average is $843.19. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 86.26%. As a group, analysts expect that Eli Lilly and Company will post 23.33 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be issued a dividend of $1.50 per share. The ex-dividend date is Friday, February 14th. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 annualized dividend and a yield of 0.69%. Eli Lilly and Company’s dividend payout ratio is currently 44.41%.

Eli Lilly and Company announced that its Board of Directors has authorized a stock buyback plan on Monday, December 9th that authorizes the company to repurchase $15.00 billion in shares. This repurchase authorization authorizes the company to reacquire up to 2% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board believes its stock is undervalued.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.